Overexpression of the receptor tyrosine kinase ErbB2/ HER2/Neu (ErbB2) occurs in 15 ± 40% of human breast cancers. To determine the function of ErbB2 signaling during normal mouse mammary gland development, we expressed a carboxyl-terminal truncated dominant negative allele of ErbB2 (ErbB2DIC) in the developing mouse mammary gland. Despite ErbB2DIC expression within mammary glands of pubescent virgin and pregnant mice, a phenotype was not observed until late in pregnancy. At 1 day post-partum, lactationally active, distended lobuloalveoli failed to form. This phenotype was exaggerated in multiparous females expressing ErbB2DIC. Immunohistochemical staining for ErbB2-DIC revealed a concordance between high levels of ErbB2DIC protein expression and the absence of lactational products within the lumens of ErbB2DIC stained lobuloalveoli. These results demonstrate that ErbB2 signaling is required for proper mammary development and lactation at parturition.
Introduction
Breast cancer is the most commonly diagnosed cancer and the second most frequent cause of cancer mortality in North American women (Parker et al., 1996) . Normal and malignant mammary epithelial growth is regulated by the activities of circulating hormones including estrogen, progesterone, and prolactin (Topper and Freeman, 1980; Vonderhaar, 1984) and locally produced growth factors (DiAugustine et al., 1997; Dickson and Lippman, 1995) . Perturbation of signaling cascades regulated by these mammary growth modulators can lead to malignant transformation of the breast.
One important mediator of growth factor signaling, the receptor tyrosine kinase ErbB2/HER2/Neu (referred to here as ErbB2) is ampli®ed and overexpressed in 15 ± 40% of human breast carcinomas (Hynes and Stern, 1994) . Overexpression of ErbB2 is associated with poor prognosis, especially in patients with lymph node involvement (Hynes and Stern, 1994; Revillion et al., 1998; Slamon et al., 1987) . In phase III clinical trials of a recombinant humanized anti-ErbB2 monoclonal antibody, targeting of breast cancer cells overexpressing ErbB2 results in growth inhibition and regression of tumors (reviewed in: Nass et al., 1998 ). These results demonstrate that ErbB2 will be a valuable target for rational therapeutic treatment of breast cancer patients with tumors overexpressing ErbB2. Despite the clinical importance of ErbB2 in breast cancer, the exact function of ErbB2 signaling during normal mammary gland development has not been established.
ErbB2 is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases (Coussens et al., 1985) . Additional members of this family are the EGFR itself, ErbB3 (Kraus et al., 1989) and ErbB4 (Plowman et al., 1993) . There are at least nine dierent genes that encode growth factors belonging to the epidermal growth factor (EGF)-family. Each of these factors has a dierent intrinsic ability to bind to and activate ErbB-family receptors (reviewed in: . A ligand that binds to and activates ErbB2 has not been identi®ed. ErbB2 signaling can be activated, however, through heterodimer formation with other ligand-bound ErbB-family members. For example, the EGFR ligand, EGF does not bind to ErbB2 but does activate ErbB2 when ErbB2 is coexpressed with EGFR (Stern et al., 1986; Stern and Kamps, 1988) . This is mediated by induction of EGFR/ErbB2 heterodimers (Spivak-Kroizman et al., 1992; Wada et al., 1990) . Although each ligand-activated EGFR-family member can form a signaling dimer with most other members of this receptor family, ErbB2 is the preferred heterodimer partner (Graus-Porta et al., 1997; Tzahar et al., 1996) . Moreover, ligand stimulated receptors compete for dimer formation with ErbB2 Karunagaran et al., 1996) . The distinct signaling activities of each receptor/ligand combination results in diverse cellular responses mediated through heterodimer formation with ErbB2 (DiFiore et al., 1990; Kokai et al., 1989; . Collectively, these results support a signaling paradigm in which ErbB2 ful®lls a role as central mediator of EGFR family signal transduction.
Expression of ErbB2, its receptor signaling partners, and several ErbB2 agonists has been detected within the developing rodent mammary gland. ErbB2 is expressed within stromal and epithelial cells of virgin mouse mammary glands and lobuloalveolar epithelium from pregnant and lactating mice (DiAugustine et al., 1997; Sebastian et al., 1998; Schroeder and Lee, 1998) . Similar cellular and temporal expression patterns have been documented for EGFR (DiAugustine et al., 1997; Ederly et al., 1985; Sebastian et al., 1998; Schroeder and Lee, 1998) , ErbB3 (Sebastian et al., 1998; Schroeder and Lee, 1998; Yang et al., 1995) , and ErbB4 (Sebastian et al., 1998; Yang et al., 1995) , although the expression of ErbB4 is highest during pregnancy (Schroeder and Lee, 1998) . Likewise, the EGFR agonists, EGF (Schroeder and Lee, 1998; Snedeker et al., 1991) , TGFa (Schroeder and Lee, 1998; Snedeker et al., 1991) , and AR (Kenney et al., 1995; Schroeder and Lee, 1998) are expressed in both virgin and pregnant mammary tissue. In contrast to these ligands, signi®cant expression levels of the ErbB3 and ErbB4 ligand, NRG1, are only detected during pregnancy (Yang et al., 1995) . The variable expression of individual EGFR family members and ligands suggests that this receptor family has multiple functions during mammary gland development.
Substantial evidence supports a role for the EGFR and its ligands in mammary ductal proliferation and morphogenesis at puberty. Mammary implants containing EGF (Coleman et al., 1988; Snedeker et al., 1991) , TGFa (Snedeker et al., 1991) , or AR (Kenney et al., 1996) induce ductal morphogenesis and proliferating terminal end bud (TEB) formation in ovariectomized mice. Consistent with the proliferative eects of EGFR ligands on mammary development, inhibition of EGFR signaling with a dominant negative EGFR results in decreased ductal proliferation and impaired morphogenesis in the virgin mammary gland (Xie et al., 1997) .
In contrast to ligands for the EGFR, signaling induced by the ErbB3 and ErbB4 ligand, NRG1, is associated with mammary dierentiation. In the AU565 human breast cancer cell line, NRG1 induces a dierentiation phenotype Peles et al., 1992) which requires ErbB2 expression (Yoo and Hamburger, 1998) . Moreover, activated ErbB2 is capable of forming alveolar-like structures in mammary epithelial cells identical to those observed following NRG1 treatment (Niemann et al., 1998) . In vivo, lobuloalveoli induced by mammary implants containing NRG1, but not TGFa, produce secretory products including the milk-protein b-casein (Jones et al., 1996) . Taken together with the weak expression of NRG1 in nulliparous mice, these results suggest that NRG1 induces distinct biological responses from TGFa and that expression of NRG1 during pregnancy is coupled to ErbB2 signaling during mammary epithelial dierentiation.
The ability of ErbB2 to be activated through dimerization with all other EGFR-family members suggests that ErbB2 plays a central role in both the proliferative phase of mammary development at puberty, and mammary dierentiation during pregnancy and lactation. To elucidate the mechanisms that govern ErbB2 mediated breast development, we inactivated signaling by endogenous ErbB2 during mouse mammary gland development through transgenic expression of a mutant ErbB2 with dominant negative activity. The results demonstrate that ErbB2 signaling is required for the terminal stages of lobuloalveolar development and lactation at parturition.
Results

Expression and dominant negative activity of a truncated ErbB2
Overexpression of truncated ErbB2 lacking the entire kinase domain and C-terminal tyrosine phosphorylation sites inhibits normal ErbB2 signaling in vitro (Qian et al., 1994) and can severely compromise ErbB2-mediated tumor formation in the nude mouse (Qian et al., 1996) . We constructed a similar dominant negative mutant by replacing sequences encoding the rat ErbB2 endodomain, downstream of A694, with sequences encoding an in¯uenza virus hemagglutinin (HA) epitope-tag. These coding sequences were placed under control of the mouse mammary tumor virus (MMTV) promoter to direct transgene expression within mouse mammary epithelial cells (Figure 1a) . The resulting construct, Smethionine/cysteine and grown in the presence of 1 mM dexamethasone to activate the MMTV promoter. Immunoprecipitations were performed using an antibody directed against the ectodomain of rat ErbB2. Molecular weight markers are indicated to the left and the positions of endogenous ErbB2 and ErbB2DIC are indicated. (c) Dominant negative activity of MMTVErbB2DIC. FR3T3 cell clones transfected with empty vector (lanes 1 and 3) or MMTV-ErbB2DIC (lanes 2 and 4) were cultured with 1 mM dexamethasone for 24 h and then mock stimulated (lanes 1 and 2) or stimulated with EGF (lanes 3 and 4) for 10 min at room temperature. ErbB2 was immunoprecitated from cell lysates and probed for phosphotyrosine by Western blot analysis (upper panel). The blot was then stripped and reprobed for ErbB2 (lower panel). The positions of phosphorylated endogenous ErbB2 (P-tyr) and total endogenous ErbB2 (ErbB2) are indicated designated MMTV-ErbB2DIC, encodes a protein of 704 residues with a predicted molecular mass of 105 KDa. The ErbB2DIC protein was expressed in FR3T3 rat embryonic ®broblast cells transfected with MMTVErbB2DIC ( Figure 1b , lane 2) but not cells transfected with an empty vector ( Figure 1b , lane 1). ErbB2 is phosphorylated in response to EGF when coexpressed with EGFR (Stern et al., 1986; Stern and Kamps, 1988) . To determine the eects of ErbB2DIC expression on the transphosphorylation of ErbB2 in response to EGF, FR3T3 cell lines expressing ErbB2DIC or the MMTV vector alone were mock treated or treated with EGF. Endogenous ErbB2 was immunoprecipitated from treated cells and the levels of receptor tyrosine phosphorylation was determined by anti-phosphotyrosine Western blot analysis. ErbB2 tyrosine phosphorylation was not observed in mock treated cell lines (Figure 1c, lanes 1 and 2) . In contrast, EGF treatment resulted in high levels of ErbB2 tyrosine phosphorylation in a cell line containing the empty vector ( Figure  1c , lane 3). Tyrosine phosphorylation of ErbB2 was inhibited, however, by expression of ErbB2DIC ( Figure  1c , lane 4). Immunoprecipitation of ErbB2 from each cell treatment was con®rmed by stripping and reprobing the blot for ErbB2 ( Figure 1c , bottom panel). These results demonstrate that the ErbB2 truncation mutant, ErbB2DIC, has dominant negative activity when coexpressed with wild-type ErbB2.
Transgenic mice derived from MMTV-ErbB2DIC
To determine the eect of dominant negative ErbB2 activity within the developing mammary gland, transgenic mice were derived by injecting MMTVErbB2DIC DNA into the pronuclei of fertilized onecell zygotes from B6SJL/F2 mice. Four founders with transgene integration (determined by polymerase chain reaction; PCR) were crossed into a FVB strain and transgene expression by the F2 female ospring was determined by Northern blot analysis using an ErbB2DIC-speci®c probe. Transgene expression was detected in mid-pregnant mammary glands from ospring of the two founder transgene lines designated 5286 and 5289 (data not shown). Phenotypic analysis of mammary glands from mice expressing ErbB2DIC was performed on F3 females derived by crossing founder line 5289 F2 mice with FVB strain mice. The phenotype of line 5289 was con®rmed by analysis of a second founder line, 5286.
Expression of the ErbB2DIC transgene in the mammary gland
To determine the temporal expression pattern of ErbB2DIC, RNA was isolated from the number 4 inguinal mammary gland of developmentally staged female mice and subjected to analysis by ribonuclease protection assay (RNPA). The 320 bp ErbB2DIC riboprobe hybridizes to the extreme 3' end of the ErbB2DIC transgene, including unique sequences corresponding to the HA-tag, resulting in a protected fragment of 240 bp ( Figure 2 , lanes 1 and 4, respectively). A similar protected fragment was never detected in mammary glands from developmentally staged non-transgenic siblings (e.g. expression was ®rst detected in virgin females as they entered puberty at 5 weeks, and expression levels increased slightly with age with maximal expression in the mature nulliparous mammary gland at 14 weeks ( Figure 2 , lanes 6 ± 9). Expression levels throughout pregnancy were several-fold greater than observed within the mature virgin mammary gland (Figure 2 , lanes 10 and 11). (In other experiments, the transgene was expressed at similarly high levels beginning at day 11 post-coitus, the earliest time point assayed.) The highest level of expression, however, was observed at 1 day post-partum ( Figure 2, lane 12 ). The window of high level post-partum transgene expression was restricted, with a decrease in expression observed at both 3 and 12 days post-partum (Figure 2, lanes 13 and  14) . Mammary gland involution, following 3 days of weaning, resulted in a return of ErbB2DIC expression to pre-pregnancy levels (Figure 2, lane 15) .
Mammary gland expression of ErbB2DIC inhibits lobuloalveolar development at parturition
Mammary gland development can be broadly divided into two hormonally regulated phases: (1) ductal proliferation and branching morphogenesis in the pubescent virgin and (2) lobuloalveolar development with epithelial terminal dierentiation during pregnancy and lactation. To determine the eects of ErbB2DIC expression on mouse mammary gland development, whole mounts and histologically-stained paran-embedded sections of mammary glands from ErbB2DIC expressing virgin mice were examined at 3, 5, 7, 10 and 14 weeks of age. Despite the expression of ErbB2DIC within the virgin mammary gland after 5 weeks (Figure 2 ), we did not detect eects on terminal end-bud formation, ductal branching, ductal growth, or cellular morphology within the nulliparous mammary gland (data not shown).
With the onset of pregnancy, proliferation of lateral and terminal ductal epithelial buds initiates ductal sidebranching and the accumulation of alveolar units. At 19 days post-coitus, some lobuloalveoli were expanded in non-transgenic mice (open arrow, Figure 3a ) and the ducts become slightly distended (arrowhead, Figure  3a ). High levels of ErbB2DIC expression during pregnancy had no eect on ductal side-branching or alveolar development up to and including 17 days postcoitus (data not shown). Evidence for inhibition of alveolar growth in ErbB2DIC-expressing mice was ®rst observed at 19 days post-coitus. Although distended ducts were observed in wholemounts of ErbB2DIC expressing mice at this stage (arrowhead, Figure 3b ), the lobuloalveoli of these mice remained condensed (®lled arrow, Figure 3b) .
At 1 day post-partum, lobuloalveoli of control mice expand as the alveolar lumens become engorged with lactation products (arrow, Figure 3c ). In control mice, the ducts are obscured by the extensive expansion of lobuloalveoli. Likewise, the lobuloalveoli of multiparous control mice at 1 day post-partum were distended (arrow, Figure 3e ), but to a much greater extent than those of uniparous control mice (compare Figure 3e to Figure 3c) . A dramatic phenotype was observed in ErbB2DIC-expressing mice at 1 day postpartum. Alveoli from both uniparous and multiparous transgenic mice remained condensed (®lled arrows, Figure 3d and f). Furthermore, distended ducts were clearly visible in wholemounts from the ErbB2DIC transgenic mice at 1 day post-partum (arrowheads, Figure 3d and f), suggesting that lobuloalveolar but not ductal epithelial cells are adversely eected by ErbB2DIC expression. The ErbB2DIC phenotype observed at 1 day post-partum was accentuated in multiparous females (46 pregnancies; compare Figure  3d and 3f), presumably because multiparity results in both higher levels and more uniform transgene expression driven by the MMTV LTR. At 3 days post-partum, epithelial proliferation results in further accumulation and expansion of lobuloalveoli in control mice (Figure 3g ). Although distended lobuloalveoli were prominent within transgenic mice at 3 days postpartum, the lobuloalveoli were still much smaller when compared to control mice (Figure 3h ). The recovery of lobuloalveolar development in the ErbB2DIC transgenic mice at this stage may be related to the dramatic decrease in transgene expression observed during lactation (Figure 2 ). The ErbB2DIC expressing mammary gland was indistinguishable from nontransgenic controls at 12 days post-partum (data not shown), a stage with maximal lactation and low transgene expression.
Histological analysis of mammary glands from control mice at 19 days post-coitus revealed expanded lobuloalveoli with the accumulation of cellular and lumenal secretory lipids (arrow, Figure 4a ). In some alveoli, lumenal proteinacious material representing the early stages of terminal dierentiation and lactation was detected (open arrowhead, Figure 4a ). Although secretory lipids were detected within lobuloalveoli of ErbB2DIC expressing mice at 19 days post-coitus (arrow, Figure 4b ), the lobuloalveoli were much smaller than those of control mice. Reduced amounts of proteinacious material were detected in the lumens of lobuloalveoli from ErbB2DIC-expressing mice (open arrowhead, Figure 4b) .
At 1 day post-partum, secretory epithelium lining the lobuloalveoli of control mice is no longer cuboidal, but has a¯attened appearance, indicating that the cells have undergone secretory dierentiation (Figure 4c ). In addition, the lumens of control mice are ®lled with granular proteinacious material (open arrowhead, Figure 4c ) and a small amount of lipid indicating that normal milk production is in progress (Figure 4c ). In multiparous control animals, the lobuloalveoli are much larger than uniparous controls and the lumens are empty, presumably due to the ecient secretory process of these glands (Figure 4e) . A majority of alveoli from ErbB2DIC expressing mice at 1 day postpartum retained the cuboidal secretory structure observed at 19 days post-coitus (Figure 4b and d and data not shown). Lumenal products present in lobuloalveoli from ErbB2DIC expressing mice resemble secretory lipids typically observed during late pregnancy (compare arrows in Figure 4d and f with Figure 4a and b). Multiparity dramatically exaggerated the inhibitory eect of ErbB2DIC expression on lobuloalveolar development. Condensed lobuloalveoli with cuboidal epithelium predominated in mammary glands from multiparous transgenic females at 1 day post-partum ( Figure 4f) . At 3 days post-partum the alveolar epithelia of both transgenic and control mice are rounded as they enter the ®rst phase of post-partum proliferation (Traurig, 1967a) (Figure 4g and h) . Despite the apparent recovery of epithelial cell function, lobuloalveoli of ErbB2DIC expressing mice at 3 days post-partum remained much smaller than those of non-transgenic controls.
ErbB2DIC expression is associated with non-secreting lobuloalveoli
In contrast to the uniform structure of lactating mammary glands from non-transgenic siblings, mammary glands from ErbB2DIC-expressing mice displayed a high degree of intragland heterogeneity (Figure 5a) . A subset of alveolar clusters with cuboidal epithelial cells always lacked lumenal secretory products (arrows). In contrast, other alveolar clusters with slightly¯attened epithelium contained secretory lipids typically observed late in pregnancy (arrowheads; compare to Figure 4a ). To determine if this heterogeneity is related to ErbB2DIC expression levels, transgene expression was determined by immunohistochemistry (IHC) (Figure 5b) . Anti-HA, which recognizes the HA epitope-tagged ErbB2DIC, yielded speci®c staining of epithelium from condensed lobuloalveolar clusters (arrows, Figure 5b ). At higher magni®cations membrane staining of the same cells was observed (data not shown). The lumens of ErbB2DIC-staining lobuloalveolar clusters lacked secretory products (compare areas marked with arrows in Figure 5a and b). ErbB2DIC was never detected in epithelium of lobuloalveolar clusters which contained secretory products (arrowheads, Figure 5a and b) or non-transgenic controls (data not shown). These results demonstrate a direct concordance between detectable levels of ErbB2DIC expression and the inhibition of lobuloalveolar epithelial dierentiation and secretory activity at 1 day post-partum.
Despite the dramatic inhibition of lobuloalveolar development and secretory processes observed within mammary glands of ErbB2DIC expressing mice at parturition, milk was clearly visible within the stomachs of pups throughout lactation, and there was no apparent consequence of ErbB2DIC expression on nursing pups (data not shown). The incomplete inhibition of terminal dierentiation, resulting in functionally lactating ErbB2DIC-expressing mammary glands, may be a result of the variegated transgene expression observed at 1 day post-partum ( Figure 5b ).
Discussion
Locally synthesized EGF family hormones and their receptors play important roles in normal and neoplastic mammary development (DiAugustine et al., 1997; Dickson and Lippman, 1995) . Indeed, a large body of evidence indicates that the EGFR family member ErbB2 is a key determinant in the ontogenesis and progression of human breast cancer (reviewed in: Hynes and Stern, 1994) . In order to inactivate normal ErbB2 signaling during mammary development, we directed expression of a dominant negative ErbB2 allele (ErbB2DIC) to the developing mouse mammary gland. Although levels of ErbB2DIC expression were greater than endogenous ErbB2 throughout mouse mammary gland development (data not shown), the ®rst ErbB2DIC-speci®c phenotype, a slight defect in lobuloalveolar expansion, was observed at late gestation (19 days post-coitus). At parturition, however, the majority of the condensed alveoli of ErbB2DIC expressing mice failed to form distended lactationally active lobuloalveoli. Furthermore, there was a direct concordance between high levels of ErbB2DIC protein expression and the lack of lobuloalveolar secretory products.
ErbB2 is the preferred heterodimer partner of activated EGFR family members (Graus-Porta et al., 1997; Tzahar et al., 1996) , and, when mutated, can inactivate other ErbB-family receptors (Qian et al., 1994) . Therefore, we cannot rule out the possibility that in addition to inhibiting ErbB2 signaling, ErbB2DIC inactivates signaling by other members of the EGFR-family. Nevertheless, our results suggest that proper ErbB2 signaling is required for both the terminal stages of lobuloalveolar development and lactation at parturition.
A similar MMTV-driven dominant negative strategy has been used to inactivate EGFR signaling in the developing mouse mammary gland (Xie et al., 1997) . Dominant negative EGFR expression inhibited mammary ductal morphogenesis in the pubescent virgin mouse. Since ErbB2 is expressed within the virgin mammary gland and is the preferred heterodimer partner of ligand activated EGFR, we expected a similar phenotype in mammary glands of pubescent mice expressing ErbB2DIC. One possible explanation for the lack of an ErbB2DIC phenotype in virgin mice is that the level of ErbB2DIC expression may be below the threshold level necessary to dominantly inhibit endogenous ErbB2. In addition, the mosaic transgene expression observed in our experiments resulted in high levels of ErbB2DIC expression in only a minority of mammary epithelial cells. Growth inhibition of a subpopulation of mammary epithelial cells expressing high levels of ErbB2DIC could go undetected due to immigration and overgrowth by normal ducts.
Despite high levels of transgene expression, an ErbB2DIC phenotype was also absent during early or mid-pregnancy. This lack of phenotype during the second and most pronounced stage of mammary epithelial proliferation (Traurig, 1967b) suggests that ErbB2 signaling is also dispensable during this period of mammary epithelial proliferation. The ®nding that EGF injected i.p. into pregnant mice stimulates low levels of mammary gland ErbB2 tyrosine phosphorylation, relative to EGFR, further suggests a minimal role for ErbB2 at mid-pregnancy (Schroeder and Lee, 1998) .
The predominant phenotype associated with expression of ErbB2DIC was a failure of lobuloalveolar maturation at parturition. All four EGFR family members are highly phosphorylated at this developmental stage (Schroeder and Lee, 1998) and therefore may play a role in mammary gland development at parturition. One possibility is that ErbB2 signaling is coupled to multiple receptors at parturition, and ErbB2DIC abrogates signaling by all four receptors at this developmental stage. Alternatively, ErbB2 signaling may be preferentially coupled to NRG1-activated ErbB3 or ErbB4 or both at parturition. Unlike most EGFR ligands, NRG1 is expressed exclusively during pregnancy and at peak levels around parturition (Yang et al., 1995) . When NRG1 is injected into mice at parturition, a dramatic increase in ErbB2 and ErbB3 phosphorylation is observed (Schroeder and Lee, 1998) , suggesting that these two receptors are coupled Figure 5 Immunohistochemical localization of ErbB2DIC in the mammary gland at 1 day post-partum. Sequential sections from a 1 day post-partum mammary gland of an ErbB2DIC expressing mouse were stained with hematoxylin/eosin (a) or analysed by immunohistochemistry using a HA speci®c primary antibody (b) (see Materials and methods). ErbB2DIC expressing lobuloalveoli are indicated by arrows, and lobuloalveoli lacking signi®cant ErbB2DIC expression are indicated by arrowheads at this developmental stage. Consistent with these results, we have previously reported that NRG1 implanted within mammary glands of virgin female mice, induced the formation of alveoli with an accumulation of the lactation product b-casein (Jones et al., 1996) . In addition, ectopic expression and activation of ErbB2 signaling, in the absence of activated coreceptors, induced alveolar-like structures in cultured mammary epithelial cells identical to those induced by NRG1 treatment (Niemann et al., 1998) . Collectively, these results suggest that NRG1 plays a role in lobuloalveolar maturation and lactation by activating ErbB2 signaling at parturition.
The phenotype at parturition observed in ErbB2DIC expressing mice closely resembles defects in mice with gene disruptions in Stat5a or leukocyte commonantigen-related phosphatase (LAR). Independent laboratories reported that Stat5a (Liu et al., 1996; Teglund et al., 1998) and LAR (Schaapveld et al., 1997) are required for normal lobuloalveolar maturation and lactation at parturition. The possible coupling of ErbB2 signaling with the signaling pathways of Stat5a and LAR or both, deserves further investigation.
Substantial evidence supports the mitogenic eect of deregulated ErbB2 activity in the development and progression of human breast cancer (reviewed in: Hynes and Stern, 1994) . Results presented here, however, demonstrate that normal ErbB2 signaling within the mouse mammary gland contributes to epithelial dierentiation and lactation at parturition. These functionally distinct responses of mammary tissue to ErbB2 activation may be due to dierential activation and coupling of ErbB2 signaling with other EGFR-family members. For example, receptors linked to mitogenic signaling pathways within mammary tissue, including ampli®ed and overexpressed ErbB2 alone or in combination with EGFR, would result in an aggressive mammary carcinoma associated with poor prognosis, whereas coupling of ErbB2 signaling with a receptor associated with favorable prognostic indicators, such as ErbB4 , may indicate a less aggressive mammary tumor. Consistent with this hypothesis, our unpublished results demonstrate that ErbB4 signaling is required for mammary epithelial dierentiation, and is coupled to ErbB2 signaling at parturition. Characterization of ErbB4 signaling and other gene products associated with ErbB2 activation during mammary epithelial differentiation may lead to the identi®cation of favorable prognostic indicators associated with ErbB2 mediated mammary carcinogenesis. Furthermore, ErbB2 signaling pathways coupled to mammary dierentiation could be marshaled to antagonize the mitogenic eect of activated ErbB2 within an aggressively proliferating tumor.
Materials and methods
Plasmids
The plasmid pMMTV-ErbB2DIC containing the rat ErbB2 cDNA with a carboxyl-terminal truncation at residue 694 and an HA epitope-tag (Kolodziej and Young, 1991) fused with the mouse mammary tumor virus (MMTV) LTR (Figure 1 ) was constructed in two steps. First, the intermediate plasmid, pN-DID-HA, was generated by trimolecular ligation of EcoRI digested pcDL-SRa296 (Takebe et al., 1988) , the 2.4 kb EcoRI-NdeI fragment from the rat ErbB2 cDNA (Bargmann et al., 1986) , and the 236 bp NdeI ± EcoRI digested PCR product generated from the rat ErbB2 cDNA using a forward oligonucleotide primer upstream of the unique NdeI site and the reverse primer 5' GAATGAAT TCAGGCGTAATCAGGCACATCGTATGGGTACAGCC-TACGCATCGTATAC. The modi®ed rat ErbB2 cDNA was then subcloned, to generate the plasmid pMMTV-ErbB2DIC, via a trimolecular ligation involving HindIII ± EcoRI digested pMMTV-Sv40-Bssk (pMMTV-GAL4/236-SV40 minus the GAL4/236 gene) (Ornitz et al., 1991) generously provided by Philip Leder, the 530 bp HindIII ± AatII digested PCR product generated from pN-DID-HA using the forward primer with a 5' HindIII linker 5'-CTAAGCTTCAATGAT-CATCATGGAGCT-3' and the reverse primer 5'-GGGGCA-CAAGGTGGACAGGC-3', and the 3' ca. 1.6 kb AatII ± EcoRI fragment from pN-DID-HA.
The plasmid pBI-ErbB2DIC, which served as a riboprobe template was generated as follows. The 236 bp 3' NdeI (site ®lled with T4 DNA pol)-EcoRI fragment from pMMTVErbB2DIC was ligated to SmaI-EcoRI digested pBluescript I S/K (Stratagene) destroying the NdeI and SmaI sites in the process.
Immunoprecipitation and Western blot analysis
FR3T3 cell lines stably expressing ErbB2DIC, were produced by calcium phosphate transfection of 5 mg of pMMTVErbB2DIC together with 0.5 mg of pLXSN (Miller and Rosman, 1989) , which carries a neomycin resistance gene. Transfected cells were selected in 1 mg/ml of G418 and maintained in 200 mg/ml. Stable cell clones in 60 mm dishes were metabolically labeled, in the presence of 1 mM dexamethasone, by incubating for 16 h with 100 mCi of 35 Smethionine/cysteine in vitro cell labeling mix (Amersham). Labeled cells were lysed on ice in RIPA buer (10 mM Tris, pH 7.4, 150 mM NaCl, 1% deoxycholate, 1% NP-40, 0.1% sodium dodecyl sulfate, with 1 mM phenylmethylsulfonyl uoride, and 1% aprotinin) and immunoprecipitations were performed by adding 1 mg of anti-c-neu Ab-4 (Oncogene Science) and 50 ml of preswollen protein A sepharose (Pharmacia) (Stern et al., 1986) . Precipitated proteins were resolved by SDS ± PAGE on a 12% acrylamide gel and the resolving gel was processed in Opti¯uor (National Diagnostics) according to the manufacturer's instructions.
For phosphotyrosine and ErbB2 Western blot analysis FR3T3 cell lines expressing ErbB2DIC or containing empty vector in 100 mm dishes were incubated in growth media containing 0.2% calf serum for 12 h. The cells were washed once with phosphate buered saline (PBS; 15 mM Na 2 HPO 4 , 1.5 mM KH 2 PO 4 , 137 mM NaCl, 3 mM KCl, pH 7.2) and mock or EGF treated for 10 min at room temperature by adding 2.0 ml of PBS or 2.0 ml of PBS containing 250 ng of human recombinant EGF (Collaborative Biomedical), respectively. Treated cells were lysed on ice in RIPA buer containing 1 mM pervanadate. ErbB2 was immunoprecipitated from lysate containing 300 mg of protein and analysed by SDS-PAGE as described above. Phosphotyrosine Western blot was performed using mouse monoclonal antibody 4G10 (Upstate Biotechnology) diluted to 1 mg/ml using procedures described previously (Stern et al., 1986) . The blot was stripped of primary antibody as described by the manufacturer (Pierce) and was reprobed for ErbB2 with Neu antibody C-18 (Santa Cruz) diluted to 0.2 mg/ml.
Generation of MMTV-ErbB2DIC transgenic mice
For microinjection, pMMTV-ErbB2DIC was digested at unique SalI ± SpeI sites and the circa 6.3 kb fragment containing the MMTV LTR, a 600 bp 5' untranslated region of c-Ha-ras, the truncated rat ErbB2 cDNA with carboxyl-terminal HA epitope-tag, and SV40 3' mRNA processing signals, was separated from vector sequences by agarose gel electrophoresis followed by puri®cation with a gel extraction kit (Qiagen). The DNA fragment was microinjected into the pronuclei of B6SJL/F2 fertilized one-cell zygotes at a concentration of 12 mg/ml in 10 mM Tris, pH 7.5, 0.1 mM EDTA by Carole Pelletier, under the direction of Dr David Brownstein, at the Transgenic Mouse Shared Resource of the Yale University School of Medicine.
Identi®cation of transgenic mice by polymerase chain reaction (PCR)
Transgenic progeny were identi®ed by PCR analysis of DNA isolated from tail biopsies. Brie¯y, tail segments biopsied from 3-week-old weaned mice were incubated overnight at 558C in 50 mM Tris, pH 8.0, 100 mM EDTA, 100 mM NaCl, 1% SDS, and 500 mg/ml proteinase K and extracted with phenol/chloroform before ethanol (EtOH) precipitation. PCR analysis using 32 cycles at 948C for 1 min 15 s, 568C for 2 min 15 s, and 728C for 3 min 15 s in a PTC-100 programmable thermal cycler (M J Research, Inc.) was performed with 2 mg of tail DNA in a ®nal volume of 100 ml containing 10 mM Tris, pH 9.0, 50 mM KCl, 2.5 mM MgCl 2 , 200 mM of each deoxynucleotide, 0.15 mM of each primer, and 2.5 U Taq polymerase (Boehringer Mannheim). Primers for the ampli®cation of a 763 bp MMTV-ErbB2DIC fragment were 5' GGCCTGGGGATCCACTCGCTGGGG, corresponding to nucleotides 1364 to 1388 of the rat ErbB2 ORF (Bargmann et al., 1986) and 5' GGCGTAATCAGG-CACATCGTATGG which hybridizes to the 3' terminal HA 12CA5 epitope of MMTV-ErbB2DIC. Primers for the ampli®cation of a ca. 500 bp mouse b-casein exon 7 fragment served as a PCR internal control (Li et al., 1997) .
Riboprobe synthesis and puri®cation
Where possible, buers used for riboprobe synthesis and transcript puri®cation were pretreated with diethyl pyrocarbonate (DEPC) using standard procedures. For RNase protection assay (RNPA) the DNA template was linearized and contaminating ribonucleases were inactivated by protease treatment at 378C for 1 h in 10 mM Tris, pH 8.0, 50 mM NaCl, 5 mM EDTA, 0.6% SDS, and 150 mg/ml protease K. In vitro transcription and subsequent DNase treatment were performed using a MAXIscript in vitro transcription kit (Ambion) with 1 mg of template DNA exactly as described by the manufacturer. Full-length transcripts fractionated on a 6% polyacrylamide, 8 M urea gel, were excised, and eluted into 700 ml of 500 mM NH 4 OAc, 1 mM EDTA, and 0.1% SDS at 378C for 3 h.
RNA isolation and RNase protection assay
For isolation of mammary gland RNA, 0.2 g of tissue from the number 4 inguinal mammary gland was snap frozen in liquid N 2 and stored at 7708C until use. RNA was isolated from frozen tissue by homogenization in 4.0 ml of TRIzol (Gibco-BRL) with a glass homogenizer using a type B pestle (Janke and Kunkel KIKA-Labortechnik) using the exact procedure as described by the manufacturer. Isolated RNA was resuspended into DEPC (Sigma) treated ddH 2 O and stored at 7708C until use.
For RNPA analysis, 20 mg of total RNA was precipitated with 5610 5 c.p.m. of riboprobe. The same amount of t-RNA (Gibco-BRL) precipitated with riboprobe served as a negative control. Riboprobe hybridization, RNA digestion, and isolation of RNA/probe hybrids, were performed using the RPA II ribonuclease protection assay kit (Ambion) exactly as described by the manufacturer. Probe protected RNA fragments were separated on a 6% polyacrylamide 8 M urea gel and, without additional processing, the gel was exposed to XAR-5 (Kodak) x-ray ®lm at 7708C for 24 ± 48 h.
Whole-mount staining of mouse mammary glands
The entire number 4 inguinal mammary gland was spread onto a glass microscope slide, ®xed in acidic ethanol and stained in carmine solution exactly as described previously (Jones et al., 1996) .
Tissue preparation for histological analysis
For hematoxylin/eosin staining and immunohistochemistry (IHC) a portion of the number 4 inguinal mammary gland was spread onto a glass microscope slide and ®xed in freshly prepared 4% paraformaldehyde in PBS (15 mM Na 2 HPO 4 , 1.5 mM KH 2 PO 4 , 137 mM NaCl, 3 mM KCl, pH 7.2) overnight at 48C. The ®xed tissue was rinsed in ddH 2 O and partially dehydrated through an ascending EtOH series to 70%. The samples were embedded in paran and 6 mm sections were dried onto gelatin-coated slides using standard procedures.
Immunohistochemistry
For immunohistochemical detection of HA-tagged dominant negative ErbB2, paran embedded mammary glands were dewaxed in xylene, hydrated through a descending EtOH series, and washed in PBS. Endogenous peroxidase activity was inactivated by incubating the sections in 0.5% H 2 O 2 in PBS for 15 min at room temperature followed by two washes in PBS for 5 min per wash. Non-speci®c binding sites were blocked for 30 min at room temperature with 10% rabbit serum in PBS. Sections were sequentially incubated ®rst with 50 ml of 10% rabbit serum in PBS containing 1 mg of anti-HA high anity rat monoclonal antibody (Boehringer Mannheim) overnight at 48C, then 50 ml of 10% rabbit serum in PBS containing 1 mg of biotinylated goat anti-rabbit lgG (Vector) for 1 h. at room temperature, and ®nally 50 ml biotin-avidin-peroxidase complex generated in PBS using a Vectastain Elite ABC kit (Vector) for 30 min at room temperature. Between each reagent, the sections were washed three times in PBS for 15 min per wash. Peroxidase activity was detected by incubating the sections for 7 min with 200 ml of DAB substrate (Vector). Negative controls included similarly processed mammary gland paran sections from a non-transgenic sibling at 1 day post-partum and sections from ErbB2DIC-expressing mammary glands processed without anti-HA primary antibody. Sections were lightly counterstained in hematoxylin (Polysciences), dehydrated through an ascending EtOH series, cleared in xylene, and coverslipped with permount (Fisher).
